Cara Therapeutics. has filed a patent for formulations enabling oral delivery of kappa opioid receptor agonists, including CR845, for treating conditions like pain and inflammation. The formulations consist of the agonist, an oligosaccharide stabilizing agent, and an optional absorption enhancer, encapsulated in capsules. GlobalData’s report on Cara Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cara Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cara Therapeutics, Tetrapeptide derivatives was a key innovation area identified from patents. Cara Therapeutics's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Oral formulation for kappa opioid receptor agonist

Source: United States Patent and Trademark Office (USPTO). Credit: Cara Therapeutics Inc

A recent patent application (Publication Number: US20230381265A1) discloses a novel formulation designed for the oral delivery of a kappa opioid receptor agonist. The formulation includes a particle containing the kappa opioid receptor agonist and an oligosaccharide, with the agonist embedded in the oligosaccharide. Specifically, the kappa opioid receptor agonist CR845 is mentioned, along with the oligosaccharide trehalose. Additionally, the formulation may include absorption enhancers such as sodium caprate, various excipients, and carriers to enhance efficacy and bioavailability.

Moreover, the patent application outlines a method for manufacturing the formulation, involving spray drying a mixture of the agonist and oligosaccharide to form particles or coating the mixture onto beads or microbeads. The method also includes encapsulating the coated beads or microbeads in a capsule, with the option of adding an enteric coating for specific delivery requirements. This innovative approach aims to improve the oral delivery of kappa opioid receptor agonists, potentially enhancing their therapeutic effects and patient compliance.

To know more about GlobalData’s detailed insights on Cara Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies